Score
66
Technically Moderately Bullish
Advice
Sun Pharmaceutical Industries Share Price - 1 Year Trend
Sun Pharmaceutical Industries Price Change Analysis
-
P/E Ratio
97
-
PEG Ratio
0.2
-
Market Cap Cr
216875.9
-
Price to Book Ratio
113.5
-
EPS
9.3
-
Dividend
750 ()
-
Relative Strength Index
51.38
-
Money Flow Index
40.12
-
MACD Signal
-1.85
-
Average True Range
23.72
Investment Ratings
-
Master Rating:
-
EPS Strength
Price Strength
Buyer Demand
Group Rank
Result Highlights
Sun Pharmaceutical Industries Synopsis
NSE-Medical-Generic Drugs
Sun Pharma. is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 12803.21 Cr. and Equity Capital is Rs. 239.93 Cr. for the Year ended 31/03/2021. Sun Pharmaceutical Industries Ltd. is a Public Limited Listed company incorporated on 01/03/1993 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1993PLC019050 and registration number is 019050.-
Market Cap
216,875.89
-
Sales
14,399.40
-
Shares in Float
-
No of Funds
935
-
Yield
1
-
Book Value
8.66
-
U/D Vol Ratio
1.1
-
LTDebt/Equity
19
-
Alpha
0.11
-
Beta
0.72
| Owner Name | Jun-21 |
|---|---|
| Promoters | 54.48% |
| Mutual Funds | 12.03% |
| Insurance Companies | 9.44% |
| Foreign Portfolio Investors | 11.5% |
| Financial Institutions/ Banks | 0.47% |
| Individual Investors | 7.22% |
| Others | 4.86% |
| Name | Designation |
|---|---|
| Mr. Israel Makov | Chairman |
| Mr. Dilip S Shanghvi | Managing Director |
| Mr. Sailesh T Desai | Whole Time Director |
| Mr. Kalyanasundaram Subramanian | Whole Time Director |
| Mr. Sudhir V Valia | Non Exe.Non Ind.Director |
| Dr. Pawan Goenka | Independent Director |
| Mr. Rama Bijapurkar | Independent Director |
| Ms. Rekha Sethi | Ind. Non-Executive Director |
| Mr. Vivek Chaand Sehgal | Ind. Non-Executive Director |
| Mr. Gautam Doshi | Ind. Non-Executive Director |
Sun Pharmaceutical Industries Forecast
Price Estimates
Eps And Sales Estimates
Sun Pharmaceutical Industries Financials
- Quarterly P&L
- Annual P&L
- Cash Flow
- Balance Sheet
- Ratios
Sun Pharmaceutical Industries Technicals
EMA & SMA
CURRENT PRICE
EMA
Sun Pharmaceutical Industries Resistance and Support
Sun Pharmaceutical Industries Delivery and Volume
Sun Pharmaceutical Industries Price Change Analysis
Corporate Action
Similar Stocks
| Company Name | 52 Week () |
Market Price () | Volume |
|---|
Videos
About Company
News
FAQs
Sun Pharmaceutical Industries (Sun Pharma) has an operating revenue of INR 36,704.43 Cr. on a trailing 12-month basis. Annual revenue growth of 3% is not great, Pre-tax margin of 8% is okay. Institutional holding has gone up in the last reported quarter is a positive sign. Analyst Recommendation on Sun Pharmaceutical Industries (Sun Pharma): HOLD
Dilip Shanghvi is the Managing Director of Sun Pharmaceutical Industries (Sun Pharma).
The ROE of Sun Pharmaceutical Industries (Sun Pharma) is 6% which is fair but needs improvement.
Sun Pharmaceutical Industries (Sun Pharma) has a reasonable debt to equity of 2%, which signals a healthy balance sheet.
The PE ratio of Sun Pharmaceutical Industries (Sun Pharma) is 81.5.
Sun Pharmaceutical Industries share price is